noom cost semaglutide Weight-loss company pivots to smaller doses of compounded Wegovy Noom to Sell Microdoses of

Este produto para seu uso pessoal e no deve ser transferido para outras pessoas

CEO Brian Niccol explained to Axios in June that the new innovation is geared toward a number of consumer groups, such as 20-year-old males, 50-year-old females and people taking GLP-1s

S., Helms, H

doi:10.1016/j.clinme.2025.100298 226

clinical complexity slows uptake Long-acting or micro-dosages (e.g., monthly injections, microneedle patches) What changes: Improved tolerability, better adherence Where it moves : Possibly back toward DTC models if access outpaces infra Strategic shift: Less patient burden, potential wedge for intermediaries Risk: Manufacturing lag or cost may stall rollout

GLP-1 receptor drugs also have other health benefits on the body that can aid in weight loss